PubMed Glucagon-like receptor agonists and next-generation incretin-based medications Current review for incretin-based obesity medications and cardiometabolic effects
During the four-year follow-up period, 7 out of 113 individuals on the placebo developed primary liver cancer, while none of the 113 subjects supplemented with selenium developed liver cancer (80)
Machado NJ, Ardais AP, Nunes A, Szab EC, Silveirinha V, Silva HB, et al
Lynda Scammell, the head of borderline products at the MHRA, said: Where medicinal claims are made, or products are being used in a way which brings them within the definition of a medicinal product under the Human Medicines Regulations 2012, a peptide-containing product must hold a marketing authorisation to be legally sold or supplied in the UK